Certificate under Reg 74(5) of SEBI(DP) Regulations, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has submitted a routine quarterly compliance certificate to BSE for the period January 1 to March 31, 2025. The certificate was issued by their Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirming that share certificates received from depository participants for dematerialization were properly processed within the 15-day deadline. The dematerialized securities were listed on the stock exchange, original physical certificates were mutilated and cancelled, and the depository's name was recorded as the registered owner. This is a standard regulatory filing required every quarter and does not involve any business decision, financial change, or corporate action.
No impact on shareholders or stock price. This is a purely procedural filing confirming that the company's share dematerialization process is running smoothly and in line with SEBI rules. Investors can ignore this for any investment decision-making.